CytoMed Therapeutics Limited

Hi, good morning and good evening, everyone. Can you hear me? Yes, yes, Yifeng can. Yeah, sorry, we have some technical issue just now. So I would like to thank you for your time to join our earnings call today. Yeah, this is Yvonne, the CFO of Apostatomed Therapeutics. And I have my team with me. So I would like to proceed with our presentation. Yeah. Before kick-off of my presentation, please note that we will be making forward-looking statements today, which may differ materially from actual results. Please review our legal disclaimer included in all our presentations carefully. I will now give you a broad overview of the 6-month ended 30 June 2025 financial performance. Our revenue increased by 100% to $156,000 for the 6 months ended 30 June 2025. Other operating income decreased by 8.5% year-on-year. We reported a net loss of $2.25 million in 2025. Our net loss will be reduced to $1.44 million if the share-based payment, net currency exchange losses, the fair value losses on Warren Liability and the costs associated with being a publicly listed company are excluded. Loss per share was $0.19 for 6 months ended 30 June 2025. As at 30th June 2025, we have cash and bank balances of $2.86 million. Our MTS stood at $7.15 million. We move on to the next slide. The table shows the financial performance for the 6 months ended 30th June 2024 and 2025. In first half of 2025, we started generating revenue of $156,000 from private blood banking services after acquiring the license and certain assets under IPSC depository. This is one of our subsidiary in Malaysia. Other operating income decreased by 8.5%. from $422,000 in first half 2024 to $336,000 in first half 2025. This decrease was mainly driven by a reduction of $105,000 in interest income from the placement of IPO proceeds in fixed deposit and partially offset by an increase of $71,000 in research income. Other gains or losses net, the group reported other gains of $361,000 in first half 2024, compared to other losses of $273,000 in first half 2025. The decrease was mainly due to the net loss in currency exchange of $402,000 and a net loss of $227,000 in fair value changes on warrant liabilities. Research expenses increased by 19.3% from $974,000 in first half 2024 to $1.16 million in first half 2025. The increase was mainly due to the increase in employee benefit. higher preclinical expenses, increase in clinical trial expenses, and also in the facility-related expenses. This is partially offset by a reduction in depreciation expenses. Employee benefit expenses increased by $86,000 from $299,000 in first half 2024 to $386,000 in first half 2025. The increase was mainly due to the recognition of share-based compensation amounting to $87,000. Other expenses were $558,000 and $832,000 in first half 2024 and first half 2025 respectively. The increase of $274,000 was mainly due to share-based payment of $361,000, higher investor relationship expenses of $24,000, and partially offset by a reduction of $94,000 in company insurance expenses. we reported a net loss of $1.09 million in first half 2024 compared to net loss of $2.25 million in first half 2025. Net loss will be reduced to $1.44 million if the share-based payment, net currency action losses, the fair value losses on warrant liability, and the costs associated with being a public-listed company are excluded. Yeah, this table shows our balance sheet for 31st December 2024 and 30th June 2025. As at 31st December 2024, we had cash and bank balances of $4.97 million compared to $2.86 million as at 30th June 2025. Warrant liability were 12,000 and 88,000 assets, 31st December 2024 and 30th June 2025, respectively. There are 72,371,000 Warren outstanding assets, 30th June 2025. Style value changes on the Warren liability of $76,000 were recorded in the Statement of Profit and Loss account in first half of 2025. Share-based payment reserves were $448,000 as at 30 June 2025, arising from granting of ordinary shares to employee and service providers. Our MTA stood at $8.95 million as at 31 December 2024, compared to $7.15 million as at 30 June 2025. I will now proceed to update on our pipeline progress. So for our first project, CTM N2D, this is the Ka-Gamma Delta T. Currently, we have a clinical trial with Pan-UH Singapore. We have completed the dose level 1 in June 2025 and now proceeding with the dose level 2. And we target to complete the phase 1 trial in 2026. for our project number two ipsc gd and kt is still under preclinical study project number three ctm gdt this is the unmodified gamma delta t cell the ind application is ongoing for project number four ctm msc for cartilage injury We are collaborating with the Singapore hospital to do a preclinical study and trying to apply for the clinical trial in Singapore. For our 2025 and beyond outlook, we have published in a peer-reviewed journal in September 2025 for the collaboration with MD Anderson Cancer Center on preclinical studies, evaluating our second project, CTM-GDG for lymphoma. We have also announced this press release today, just only at 7 a.m. We are also trying to apply the GDT trial in Malaysia and also elsewhere. Collaboration with international parties with income potential. Also in August, we have signed the ATM agreement with Liberty to raise up to US$4.3 million. We are also rebranding our Cops.Banking business as Longevity Bank. This is our TGMP manufacturing facility. It has been audited by the MOH of Malaysia. So this is our longevity bank facility which we acquired last year. So I will play the video to show you the facility. We are now open for the Q&A session. Hi, do you have any questions? Yeah, can I end this meeting if we do not have received any questions? Yeah, thank you so much for your attendance. Yeah, we will end our earnings call for today. Thank you so much.